ROCHESTER, Minn. -- Mayo Clinic scientists have identified a specific protein implicated in drug resistance, as well as a possible therapeutic tool. Their work appears in the EMBO Journal.
The team led by Haojie Huang, Ph.D., a Mayo Clinic tumor biologist within Mayo Clinic's Center for Biomedical Discovery identified the role of FOXO1 in chemotherapy resistance.
They also identified a potential therapeutic tool by engineering a peptide, which is a short segment of amino acids.
Taxanes: response and resistance
Cancer medications come in many forms. One family of chemicals called taxanes is used to treat advanced cancers. However, over time taxanes can become less effective. Cancer cells reroute communication signals down other pathways. In this study, the authors looked at how this rerouting, or resistance, occurs in relation to the activity of enzymes called kinases.
Cells need energy to function. Kinase enzymes help by trading chemicals back and forth on specific molecules, often proteins. This activity fuels cellular functions. The authors examined the serine/threonine kinase AKT. AKT's actions generally help cells survive. But when it goes awry, this kinase plays a central role in many types of cancer. Drugs that shut down AKT have great therapeutic promise. But, because of the complexity inherent in cellular communication, those therapies themselves instead may allow cancer to survive.
In this new study researchers treated cancer cells with taxanes, which block, or inhibit, AKT action. They found that taxanes prevent a protein called FOXO1 from migrating out of the cell's nucleus. When FOXO1 stays put in the nucleus, another protein, ERK, becomes inappropriately active and kicks off signals that help cancer survive and develop resistance.
"This is why, despite great therapeutic promise, none of the AKT inhibitors have been approved by the Food and Drug Administration for anticancer use in clinic," explains Dr. Huang.
But, when FOXO1 does migrate out of the nucleus, it attaches to a scaffolding protein called IQGAP1. That binding action blocks the activation ERK and prevents chemotherapy resistance.
"We also found that cotreatment with a taxane and a small FOXO1-derived peptide inhibitor blocks ERK activation and tumor growth," says Dr. Huang. "Uncovering this new and important mechanism of drug resistance may, one day, allow us to develop new therapeutics to overcome the resistance to taxane and AKT inhibitory medicines in cancers which harbor genetic lesions leading to hyper-activation of AKT."
This engineered peptide inhibitor has been patented by Mayo Clinic Ventures, the commercialization arm of Mayo Clinic.
In addition to Dr. Huang, other authors are:
- Chun-Wu Pan, Mayo Clinic and Xinhua Hospital Shanghai Jiao Tong University School of Medicine
- Xin Jin, M.D., Mayo Clinic
- Yu Zhao, Ph.D., Mayo Clinic
- Yunqian Pan, Mayo Clinic
- Jing Yang, Mayo Clinic
- Jeffrey Karnes, M.D., Mayo Clinic
- Jun Zhang, M.D., Mayo Clinic
- Liguo Wang, Ph.D., Mayo Clinic
The authors reported no conflicts of interest. Funding for this work was provided by the National Institutes of health, the U.S. Department of Defense, Mayo Clinic Center for Individualized Medicine and the National Natural Science Foundation of China. Dr. Huang also receives funding from the Center for Biomedical Discovery.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, whole-person care to everyone who needs healing. For more information, visit mayoclinic.org/about-mayo-clinic or newsnetwork.mayoclinic.org.